475 assets in Plasma Cell Myeloma

Sti-1492

Taa-Specific Ctls

tqb2029

Tripril Car T Cells

Uf-Kure-Bcma Car T-Cells

vp301

Ws-Cart-Cs1

Zirconium Zr 89-Dfo-Ys5

Itacitinib

64Cu-LLP2A

[68Ga]Ga-R54

68ga-nb381

68ga-pentixather

89zr-ny008

Bcma Targeted Car T-Cells

car19-bcma dual-target car-t

cd70-targeting car-t cells

Chimeric Antigen Receptor Nk Cell Targeting Bcma

Eso-T01

Gprc5D-Car-T

Human Bcma Targeted Car-Nk Cells

Human Derived Anti-Bcma Car-T

jy232

Lvivo-Tavec400 Product

nkg2d chimeric antigen receptor nk cell

Prochlorperazine

rn1101

Senl103

Vitamin D

Lemzoparlimab

Apornemin

Bcma-Gprc5D Car-T

Bcma/Gprc5D Dual Car-T

Chimeric Antigen Receptor Modified T Cells Infusion

ct0590 car t cells

Lcar- F33S Cells Intravenous Infusion

Magrolimab

Utaa17

Rivogenlecleucel

Bcma-Ucart

Cafizomide

ct0594cp

Florbetaben

Fluorine (18F) Psma 1007

Immunoglobulin G4-Kappa, Anti-(Human Adp-Ribosyl Cyclase/Cyclic Adp-Ribose Hydrolase 1 (Ec:3.2.2.6) (Adprc 1/Cadrp Hydrolase 1, Cell Surface Antigen Cd38)), Humanized Monoclonal Antibody, Fused At Each C-Terminus Of The Heavy Chains (1-447, 1''-447'') To Attenuated Human Interferon .Alpha.-2B (Ifn.Alpha.2B) Variant (K23>R470, T106>A553, A145>D592) (448-612, 448''-612''); Gamma4 Heavy Chain Humanized Fused To Ifn.Alpha.2B (1-612) (Vh (Homo Sapiens Ighv1-69-2*01 (90.7%)-(Ighd)-Ighj4*01 (85.7%)) Cdrimgt (8.8.13) (26-33.51-58.97-109) (1-120)-Homo Sapiens Ighg4*01, G4V5 H P10 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 (231-340), Ch3 (341-445), Chs (446-447))(121-447), Fused To Ifn.Alpha.2B K23>R (470), T106>A (553), A145>D (592) (448-612)),(134-214')-Disulfide With Kappa Light Chain Humanized (1'-214') (V-Kappa (Homo Sapiens Igkv1-33*01 (83.2%)-Igkj4*01 (100%)) Cdr-Imgt (6.3.9) (27-32.50-52.89-97) (1'-107')-Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')); Dimer (226-226'':229-229'')-Bisdisulfide; Produced In Chinese Hamster Ovary (Cho) K1Sv Cells, Glycoform Alfa